scholarly journals Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase

Oncotarget ◽  
2015 ◽  
Vol 6 (30) ◽  
pp. 30317-30326 ◽  
Author(s):  
Liang Wang ◽  
Hua Wang ◽  
Jing-hua Wang ◽  
Zhong-jun Xia ◽  
Yue Lu ◽  
...  
Keyword(s):  
T Cell ◽  
Poor Prognosis ◽  
Cell Lymphoma ◽  
Post Treatment ◽  
T Cell Lymphoma ◽  
Early Relapse ◽  
Ebv Dna ◽  
Nk T Cell

scholarly journals High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients

Oncotarget ◽  
2016 ◽  
Vol 7 (22) ◽  
pp. 33035-33045 ◽  
Author(s):  
Hua Wang ◽  
Liang Wang ◽  
Wen-Jian Liu ◽  
Zhong-Jun Xia ◽  
Hui-Qiang Huang ◽  
...  
Keyword(s):  
Cell Death ◽  
T Cell ◽  
Programmed Cell Death ◽  
Poor Prognosis ◽  
Cell Lymphoma ◽  
Serum Levels ◽  
Post Treatment ◽  
T Cell Lymphoma ◽  
Early Relapse ◽  
Nk T Cell

scholarly journals Overexpression of MYC and BCL2 Predicts Poor Prognosis in Patients with Extranodal NK/T-cell Lymphoma, Nasal Type

2017 ◽  
Vol 8 (5) ◽  
pp. 793-800 ◽  
Author(s):  
Jing-hua Wang ◽  
Xi-wen Bi ◽  
Peng-fei Li ◽  
Zhong-jun Xia ◽  
Hui-qiang Huang ◽  
...  
Keyword(s):  
T Cell ◽  
Poor Prognosis ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Nasal Type ◽  
Nk T Cell

Peripheral T-Cell Lymphoma-Unspecified (PTCL-U) and NK/T-Cell Lymphoma Showed a Significantly Poor Prognosis in a Randomized Controlled Trial (RCT) JCOG9002 with Multidrug Combination Chemotherapy for Aggressive Lymphoma.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 2465-2465
Author(s):  
Tomohiro Kinoshita ◽  
Tomomitsu Hotta ◽  
Taro Shibata ◽  
Kiyoshi Mukai ◽  
Motoko Yamaguchi ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
T Cell ◽  
Clinical Features ◽  
Combination Chemotherapy ◽  
Poor Prognosis ◽  
Who Classification ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Aggressive Lymphoma ◽  
Nk T Cell

Abstract PURPOSE: To elucidate clinical features of NHL subtyped with WHO classification, and to evaluate the prognostic impact of WHO classification on aggressive lymphoma treated in an RCT. METHODS: JCOG9002 was an RCT comparing two multidrug combination chemotherapy regimens, LSG9 and mLSG4 (Int J Hematol 80:341, 2004). Major eligibility criteria were; previously untreated patients with intermediate- or high-grade NHL on WF (ATL, LbL and CTCL were excluded); CS I to IV except CS I in GI, thyroid, orbit, or Waldeyer; age 15–69. Tissue specimens were centrally reviewed by six hematopathologists and classified according to WHO classification of lymphoid tumors. Overall survival (OAS) and complete response rate (%CR) of each WHO category were analyzed. Multivariate analyses of prognostic factors influencing OAS were conducted. RESULTS: A total of 447 patients were registered between 1991 and 1995, and the central pathological review was conducted on 404 patients. Characteristics of the 404 pts include median (range) age 56 (18–69) years; male/female 63/37%, CS I+II/III+IV 31/69%; LDH N/>N 51/49%; PS 0+1/2–4 78/22%; No. of extranodal sites 0–1/1< 77/23%; IPI L/LI/HI/H 40/27/20/12%. Major clinical features, OAS and %CR of major types according to WHO classification are summarized in Table 1. Twelve patients with FL (G1+2) were ineligible in this study but included. Clinical features, response to treatment and prognosis of each subtypes showed distinct patterns. Besides, we found that PTCL-U and NK/T-cell lymphoma showed lower CR rate and poorer OAS, and these features were quite different from other PTCL such as AILT or ALCL. Clinical features in other subtypes were similar to previous reports (Blood89: 3909, 1997; J Clin Oncol16: 2780, 1998). Cox regression analysis with IPI and WHO classification in 366 pts without missing value revealed that PTCL-U and NK/T-cell lymphoma were significant prognostic factors independent from IPI. Hazard ratios of these subgroups vs IPI low risk DLBCL group are 2.66 (95% confidence interval: 1.58–4.48) and 3.21 (1.40–7.37). CONCLUSIONS: Patients with aggressive lymphoma subtyped according to the WHO classification who were treated in an RCT showed distinctive clinical features. PTCL-U and NK/T-cell lymphoma showed a significantly poor prognosis independent from IPI, warranting further investigations focusing on these two subtypes. Table 1 No of cases (%) % male Median age % stage III or IV % IPI HI/H %5-yr OAS % CR *Pts with missing value are excluded from the denominator. Only major subtypes are included in this table. DLBCL 242 (59.9) 61 58 63 37 55 71 FL, all grades 37 (9.2) 70 55 68 15 76 70 MCL 15 (3.7) 60 57 87 20 53 73 MZL 9 (2.2) 56 51 71 0 89 67 AILT 22 (5.4) 77 58 100 67 67 73 PTCL-U 23 (5.7) 65 51 83 38 22 43 ALCL 10 (2.5) 70 50 70 33 70 70 NK/T 10 (2.5) 80 52 70 25 40 40

Pilot Study of Peginterferon Alfa-2a (PEGASYS®) Concurrent Administration during Induction Chemoradiotherapy and Maintenance Therapy in Patients with EBV-Associated Extranodal NK/T Cell Lymphoma

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 5005-5005
Author(s):  
Seok-Goo Cho ◽  
Sung-Won Kim ◽  
Kyung-Sin Park ◽  
Ji-Hyang Lim ◽  
Chang-Ki Min ◽  
...  
Keyword(s):  
T Cell ◽  
Pilot Study ◽  
Maintenance Therapy ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
High Dose ◽  
Concurrent Administration ◽  
Ebv Dna ◽  
Nk T Cell ◽  
Peginterferon Alfa

Abstract Extranodal NK/T-cell lymphoma, nasal type is common in Asians rather than in Western populations. This special subtype responds poorly to intensive chemotherapy regimens or has a significant relapse rate in spite of low IPI and loco-regional staging. The presence of the EBV genome within tumor cells raised the possibility of developing therapeutic strategies directed at viral targets. The primary objectives of this prospective, single center, nonrandomized phase II trial are the evaluation of efficacy by determination of progression-free survival after concurrent administration of peginterferon alfa-2a (PEGASYS®, provided by Roche Korea) and chemoradiotherapy in patients with extranodal NK/T cell lymphoma. In addition, we evaluated the efficacy of peginterferon alfa-2a maintenance therapy for 3 years. All seven patients with newly diagnosed CD56+ EBV+ extranodal NK/T-cell lymphoma were enrolled onto a prospective clinical trial. Step 1; PEGASYS® 180 mcg was administered once weekly on D1, D8 of ProMACE-CytaBOM. 1, 2 cycles. Step 2; PEGASYS® 180 mcg will be administered once weekly on D1, D8, D15, D22 of involved-filed irradiation 3600 cGy (180 cGy × 20, for 4 weeks). Step 3; PEGASYS® 180 mcg will be administered once weekly on D1, D8 of ProMACE-CytaBOM. 3, 4 cycles. Step 4; PEGASYS® 180 mcg will be administered every two weeks after hematologic recovery of high-dose therapy and autologous PBSCT for 3 years. In case of advanced stage and non-nasal lesion, Step 2 was omitted and ProMACE-CytaBOM was extended to 6 cycles. EBV DNA copy based on real-time PCR was monitored. Of all 7 patients, 6 patients achieved complete response and 1 patient was dead due to pneumonia during chemotherapy. With a median follow-up of 26 months (3–36 months), the 3-year PFS were 67%. Of 6 assessable patients, five patients extended to peginterferon alfa-2a maintenance therapy and four patients showed PFS. Among two relapsed patients, one patient refused a peginterferon alfa-2a maintenance therapy and eventually relapsed 3 months later. Titer of EBV DNA copy in whole blood was significantly decreased compared with the titer on initial diagnosis. The main toxicities of peginterferon alfa-2a were mild flu-like symptoms. This pilot study suggests that larger prospective randomized studies are needed to define the role of peginterferon alfa-2a concurrent administration during induction therapy and maintenance therapy in EBV-associated extranodal NK/T-cell lymphoma.

scholarly journals Prospective measurement of Epstein-Barr virus–DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type

Blood ◽  
2011 ◽  
Vol 118 (23) ◽  
pp. 6018-6022 ◽  
Author(s):  
Ritsuro Suzuki ◽  
Motoko Yamaguchi ◽  
Koji Izutsu ◽  
Go Yamamoto ◽  
Kenzo Takada ◽  
...  
Keyword(s):  
T Cell ◽  
Mononuclear Cells ◽  
Cell Lymphoma ◽  
Clinical Stage ◽  
T Cell Lymphoma ◽  
Nasal Type ◽  
Barr Virus ◽  
Ebv Dna ◽  
Nk T Cell ◽  
Epstein Barr

Abstract Epstein-Barr virus (EBV)–DNA was prospectively analyzed in plasma and mononuclear cells (MNCs) from peripheral blood in patients with extranodal natural killer (NK)/T-cell lymphoma, nasal type, to evaluate the clinical significance for diagnosis, monitoring the tumor burden, and prognostication. Thirty-three patients were enrolled, and 32 were evaluable. Pretreatment plasma and MNC EBV-DNA was detectable in 14 (range, 50-71 000 copies/mL) and 6 patients (range, 20-780 copies/μg DNA), respectively, and both were well correlated (r = 0.8741, P < .0001). Detectable plasma EBV-DNA was associated with higher clinical stage (P = .02), presence of B symptoms (P = .02), worse performance status (P = .02), and higher serum soluble IL-2 receptor level (P < .0001). Twenty-two patients attained complete response. Plasma EBV-DNA level was significantly higher in nonresponders than in responders (mean, 16 472 vs 2 645 copies/mL; P = .02). Multivariate analysis showed clinical stage (hazard ratio, 9.0; 95% confidence interval, 1.8%-45.0%) and pretreatment plasma EBV-DNA (hazard ratio, 10.6; 95% confidence interval, 1.3%-87.0%) were significant prognostic factors. Three-year overall survival of plasma EBV-DNA positive and negative patients was 42.9% and 94.4%, respectively (P = .0009). Plasma was a preferable sample for this purpose in NK/T-cell lymphoma, nasal type, and EBV-DNA level was a good indicator for response and overall survival.

Diagnostic and Prognostic Values of Serum EBV DNA in Nasal NK/T-Cell Lymphoma

2005 ◽  
Vol 133 (2) ◽  
pp. P96-P96
Author(s):  
Y HARABUCHI ◽  
H ISHII ◽  
T OGINO ◽  
T NAGATO ◽  
N BANDOH
Keyword(s):  
T Cell ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Ebv Dna ◽  
Nk T Cell

CD56-negative extranodal NK/T cell lymphoma should be regarded as a distinct subtype with poor prognosis

Tumor Biology ◽  
2015 ◽  
Vol 36 (10) ◽  
pp. 7717-7723 ◽  
Author(s):  
Liang Wang ◽  
Zhao Wang ◽  
Zhong-jun Xia ◽  
Yue Lu ◽  
Hui-qiang Huang ◽  
...  
Keyword(s):  
T Cell ◽  
Poor Prognosis ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Nk T Cell ◽  
Distinct Subtype

scholarly journals Genomic profiling of plasma circulating tumor DNA reveals genetics and residual disease in extranodal NK/T-cell lymphoma

2019 ◽  
Author(s):  
Qiong Li ◽  
Wei Zhang ◽  
Jiali Li ◽  
Jingkang Xiong ◽  
Jia Liu ◽  
...  
Keyword(s):  
T Cell ◽  
Poor Prognosis ◽  
Residual Disease ◽  
Cell Lymphoma ◽  
Medical Center ◽  
Disease Status ◽  
Circulating Tumor Dna ◽  
T Cell Lymphoma ◽  
Nk T Cell ◽  
Tumor Dna

AbstractBackgroundExtranodal NK/T-cell lymphoma, nasal type (ENTKL), is an aggressive hematological malignancy with poor prognosis. Early detection of tumors at initial diagnosis or during routine surveillance is important for improving survival outcomes. Molecular profiling of circulating tumor DNA (ctDNA) is a promising noninvasive tool for monitoring disease status. Here, we investigated the feasible of ctDNA detection in ENTKL.MethodsPlasma ctDNA was assessment were based on blood specimens that were collected from 65 patients recently diagnosed with ENKTL at the hematology medical center of Xinqiao Hospital, longitudinal samples collected under chemotherapy also included. Gene mutation spectrum of ENKTL was analyzed via cancer personalized profiling sequencing (CAPP-Seq). This study is registered with ClinicalTrials.gov (ChiCTR1800014813)ResultsFrom February 2017 to September 2019, 65 patients were enrolled, we found that the most frequently mutated genes were KMT2D (23.1%), APC (12.3%), ATM (10.8%), ASXL3 (9.2%), JAK3 (9.2%), SETD2 (9.2%), TP53 (9.2%), NOTCH1 (7.7%). The mutation frequencies of KMT2D was significantly higher in stage III-IV, and mutations in KMT2D, ASXL3 and JAK3 were significantly correlated with the metabolic tumor burden of the patients. Compared with tumor tissue DNA, ctDNA profiling showed good concordance. Serial ctDNA analysis showed that treatment with chemotherapy could decrease the number and mutation allele frequency of genes. Compared with PET/CT, ctDNA has more advantages for tracking residual disease in patients. In addition, we also found that mutated KMT2D predicted poor prognosis in patients.ConclusionCollectively, our results provide evidence that ctDNA may serve as a novel precision medicine biomarker in ENKTL.

scholarly journals Circulating Low Absolute CD4+ T Cell Counts May Predict Poor Prognosis in Extranodal NK/T-Cell Lymphoma Patients Treating with Pegaspargase-Based Chemotherapy

2019 ◽  
Vol 51 (1) ◽  
pp. 368-377 ◽  
Author(s):  
Ya-Ping Zhang ◽  
Run Zhang ◽  
Hua-Yuan Zhu ◽  
Li Wang ◽  
Yu-Jie Wu ◽  
...  
Keyword(s):  
T Cell ◽  
Poor Prognosis ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cd4 T Cell ◽  
Cell Counts ◽  
Nk T Cell
Sign in / Sign up

Export Citation Format

Share Document